EZH2 and myelodysplastic syndrome: MiRNA-21, which is recognized as a potential serum biomarker during epigenetic therapy in MDS [93], is also an up-regulator of EZH2 in human lung cancer stem cells [94], whereas miRNA-148a has recently been recognized as a down-regulator of DNMT1 in AML cells [95].